News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,241 Results
Type
Article (13762)
Company Profile (101)
Press Release (251378)
Section
Business (88049)
Career Advice (465)
Deals (15343)
Drug Delivery (67)
Drug Development (36602)
Employer Resources (49)
FDA (6289)
Job Trends (6198)
News (150218)
Policy (14026)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (32)
Alliances (23220)
ALS (36)
Alzheimer's disease (389)
Antibody-drug conjugate (ADC) (36)
Approvals (6326)
Artificial intelligence (102)
Autoimmune disease (8)
Automation (3)
Bankruptcy (149)
Best Places to Work (4372)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (19)
Brain cancer (15)
Breast cancer (74)
Cancer (583)
Cardiovascular disease (70)
Career advice (407)
Career pathing (11)
CAR-T (20)
Cell therapy (83)
Cervical cancer (4)
Clinical research (30877)
Collaboration (325)
Compensation (134)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (117)
Cystic fibrosis (35)
Data (600)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1319)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32076)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37402)
Executive appointments (358)
FDA (6683)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (204)
Gene editing (37)
Generative AI (8)
Gene therapy (99)
GLP-1 (339)
Government (1285)
Grass and pollen (2)
Guidances (15)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (10)
Immunology and inflammation (34)
Indications (12)
Infectious disease (790)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (13)
Intellectual property (45)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (79)
Lymphoma (53)
Machine learning (1)
Management (16)
Manufacturing (142)
MASH (31)
Medical device (1276)
Medtech (1278)
Mergers & acquisitions (9656)
Metabolic disorders (246)
Multiple sclerosis (19)
NASH (14)
Neurodegenerative disease (22)
Neuropsychiatric disorders (6)
Neuroscience (559)
NextGen: Class of 2025 (1586)
Non-profit (593)
Northern California (680)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (50)
Pancreatic cancer (13)
Parkinson's disease (43)
Partnered (7)
Patents (104)
Patient recruitment (28)
Peanut (10)
People (28872)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8037)
Phase II (13062)
Phase III (11725)
Pipeline (408)
Podcasts (46)
Policy (59)
Postmarket research (1401)
Preclinical (3209)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (120)
Rare diseases (158)
Real estate (2633)
Recruiting (17)
Regulatory (10086)
Reports (14)
Research institute (564)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (7)
Schizophrenia (35)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (31)
Southern California (692)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (29)
United States (6866)
Vaccines (150)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (53)
Last 7 days (267)
Last 30 days (981)
Last 365 days (12069)
2025 (3037)
2024 (12509)
2023 (14246)
2022 (19558)
2021 (20069)
2020 (19039)
2019 (14888)
2018 (11717)
2017 (13889)
2016 (13131)
2015 (15476)
2014 (12420)
2013 (10592)
2012 (11400)
2011 (11923)
2010 (10893)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (54)
Arkansas (3)
Asia (20092)
Australia (2605)
California (1638)
Canada (872)
China (229)
Colorado (65)
Connecticut (65)
Delaware (53)
Europe (39364)
Florida (304)
Georgia (36)
Idaho (9)
Illinois (185)
India (14)
Indiana (128)
Iowa (1)
Japan (86)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1416)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (720)
New Mexico (7)
New York (480)
North Carolina (379)
North Dakota (2)
Northern California (680)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (412)
Puerto Rico (8)
Rhode Island (7)
South America (502)
South Carolina (2)
Southern California (692)
Tennessee (34)
Texas (219)
Utah (33)
Virginia (70)
Washington D.C. (29)
Washington State (112)
Wisconsin (14)
265,241 Results for "inmed pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
January 22, 2025
·
5 min read
Press Releases
InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration
February 3, 2025
·
5 min read
Press Releases
InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
February 13, 2025
·
12 min read
BioMidwest
InMed AI Receives FDA 510(k) clearance for NeuroShield™
InMed.AI (InMed Prognostics Inc.), a pioneer in AI-driven predictive analytics using multi-modal data including text, signal, and image (US Patent No.11263749) and the creator of an end-to-end fully automated organ agnostic imaging platform, announced that it has received the US Food and Drug Administration (FDA) 510(k) clearance for NeuroShield™.
November 13, 2023
·
4 min read
Business
InMed Pharmaceuticals Reports First Quarter Fiscal 2023 Financial Results and Provides Business Update
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the first quarter of fiscal year 2023, ended September 30, 2022.
November 11, 2022
·
11 min read
InMed Provides Update on Management Changes
InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces that Sarah Li has been promoted to Vice President of Accounting and Controller at InMed.
November 17, 2022
·
3 min read
Business
InMed Provides Business Update and Milestones for 2023
InMed Pharmaceuticals Inc today outlines key accomplishments from 2022 and provides business update and catalysts for 2023.
January 10, 2023
·
9 min read
Business
InMed Pharmaceuticals Reports Full Year Fiscal 2022 Financial Results and Provides Business Update
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today reported financial results for the fiscal year ended June 30, 2022.
September 23, 2022
·
18 min read
Business
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.
September 19, 2022
·
2 min read
Policy
InMed Submits Form 12b-25
InMed Pharmaceuticals Inc., a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, announces it has submitted a Form 12b-25 with the U.S. Securities and Exchange Commission in connection with its Quarterly Report on Form 10-Q for the period ended December 31, 2022.
February 9, 2023
·
3 min read
1 of 26,525
Next